MX2016005348A - Compuestos novedosos. - Google Patents

Compuestos novedosos.

Info

Publication number
MX2016005348A
MX2016005348A MX2016005348A MX2016005348A MX2016005348A MX 2016005348 A MX2016005348 A MX 2016005348A MX 2016005348 A MX2016005348 A MX 2016005348A MX 2016005348 A MX2016005348 A MX 2016005348A MX 2016005348 A MX2016005348 A MX 2016005348A
Authority
MX
Mexico
Prior art keywords
novel compounds
rory
retinoid
therapy
directed
Prior art date
Application number
MX2016005348A
Other languages
English (en)
Inventor
Amanda Jennifer Campbell
Joelle Le
Birault Veronique
Anthony Harrison Stephen
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2016005348A publication Critical patent/MX2016005348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se dirige a formas cristalinas de un compuesto que tiene actividad moduladora gamma del receptor huérfano relacionado con retinoide (RORy), procedimientos para su preparación, composiciones farmacéuticas que contienen las mismas y su uso en terapia.
MX2016005348A 2013-10-25 2014-10-23 Compuestos novedosos. MX2016005348A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895470P 2013-10-25 2013-10-25
PCT/US2014/061864 WO2015061515A1 (en) 2013-10-25 2014-10-23 Novel compounds

Publications (1)

Publication Number Publication Date
MX2016005348A true MX2016005348A (es) 2016-08-11

Family

ID=52993531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005348A MX2016005348A (es) 2013-10-25 2014-10-23 Compuestos novedosos.

Country Status (10)

Country Link
US (1) US20160257664A1 (es)
EP (1) EP3060553A4 (es)
JP (1) JP2016534085A (es)
KR (1) KR20160068799A (es)
CN (1) CN105636941A (es)
AU (1) AU2014340107B2 (es)
CA (1) CA2928537A1 (es)
MX (1) MX2016005348A (es)
RU (1) RU2016119998A (es)
WO (1) WO2015061515A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2928885T3 (en) 2012-12-06 2017-05-15 Glaxo Group Ltd MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
CR20160549A (es) 2014-05-28 2017-04-28 Glaxosmithkline Ip Dev Ltd COMPUESTOS DERIVADOS DE N-(3-((4-(TETRAHIDROFURANO/TETRAHIDROPIRANO-3-CARBONIL)PIPERAZIN-1-IL) METIL)FENIL)FORMAMIDA ACTIVOS COMO MODULADORES DEL RECEPTOR HUÉRFANO GAMMA (RORy) RELACIONADOS CON RETINOIDES.
JP2017516800A (ja) 2014-05-28 2017-06-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
BR112016027732B1 (pt) 2014-05-28 2023-11-07 Glaxosmithkline Intellectual Property Development Limited Composto modulador do receptor gama, composição farmacêutica que compreende o referido composto, bem como uso do mesmo para o tratamento de doenças inflamatórias e autoimunes mediadas por rory
CN107614062A (zh) 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE296811T1 (de) * 1997-07-11 2005-06-15 Smithkline Beecham Plc Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung
US6080587A (en) * 1998-01-23 2000-06-27 Eli Lilly And Company Method for preparing and selecting pharmaceutically useful sulfur-bridged bi- and triaromatic ring compounds from a structurally diverse universal library
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012148588A2 (en) * 2011-04-27 2012-11-01 Glaxosmithkline Llc CRYSTAL FORM OF N-{3-[5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1-DIMETHYLETHYL)-1,3-THIAZOL-4yl}-2-FLUOROPHENYL}-2,6-DIFLUOROBENZENESULFONAMIDE
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
CA2871534A1 (en) * 2012-04-27 2013-10-31 Glaxo Group Limited Novel compounds

Also Published As

Publication number Publication date
US20160257664A1 (en) 2016-09-08
CN105636941A (zh) 2016-06-01
EP3060553A4 (en) 2017-03-29
WO2015061515A1 (en) 2015-04-30
RU2016119998A (ru) 2017-11-30
AU2014340107B2 (en) 2017-08-31
EP3060553A1 (en) 2016-08-31
KR20160068799A (ko) 2016-06-15
JP2016534085A (ja) 2016-11-04
CA2928537A1 (en) 2015-04-30
AU2014340107A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
PH12014502414A1 (en) Novel compounds
PH12016501151A1 (en) Nrf2 regulators
PH12015502615B1 (en) Chemical compounds
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX2019015744A (es) Composiciones farmaceuticas.
GEP20207102B (en) Sulfonamides as modulators of sodium channels
UA110354C2 (uk) Противірусні сполуки
GEP20166438B (en) Imidazopyrrolidinone compounds
GEP20196942B (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
EA201300388A1 (ru) Соединения замещенного бензамида
MX2017015741A (es) Moduladores de ror gamma (ror?).
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX2016005348A (es) Compuestos novedosos.
GEP201706710B (en) Imidazopyridazine derivatives as gabaa receptor modulators
NZ731118A (en) Dopamine d3 receptor antagonists compounds
GEP201706621B (en) Benzamides
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
MX2017015739A (es) Moduladores de ror gamma (ror?).
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CA2891755C (en) Substituted pyrido-piperazinone derivatives as gamma secretase modulators
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX364400B (es) Compuestos de tetraciclina.
MX362879B (es) Usos novedosos.
MY180006A (en) Azetidinyloxyphenylpyrrolidine compounds